Longeveron Inc. (NASDAQ:LGVN) Director Rock Soffer acquired 12,000 shares of the company’s stock in a transaction on Wednesday, October 13th. The stock was purchased at an average cost of $3.76 per share, for a total transaction of $45,120.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Rock Soffer also recently made the following trade(s):
- On Monday, October 11th, Rock Soffer acquired 3,900 shares of Longeveron stock. The stock was purchased at an average cost of $3.45 per share, for a total transaction of $13,455.00.
LGVN traded up $0.22 during trading on Wednesday, hitting $3.81. The stock had a trading volume of 181,790 shares, compared to its average volume of 423,842. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.12 and a current ratio of 10.12. The company’s 50-day moving average price is $3.89 and its 200 day moving average price is $5.62. Longeveron Inc. has a twelve month low of $3.20 and a twelve month high of $12.48.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Longeveron by 811.5% during the 2nd quarter. Vanguard Group Inc. now owns 131,260 shares of the company’s stock worth $1,067,000 after purchasing an additional 116,860 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Longeveron during the 2nd quarter worth $311,000. Matrix Asset Advisors Inc. NY boosted its position in shares of Longeveron by 16.7% during the 2nd quarter. Matrix Asset Advisors Inc. NY now owns 35,000 shares of the company’s stock worth $285,000 after purchasing an additional 5,000 shares in the last quarter. Geode Capital Management LLC purchased a new stake in shares of Longeveron during the 2nd quarter worth $120,000. Finally, Private Capital Group LLC boosted its position in shares of Longeveron by 140.0% during the 3rd quarter. Private Capital Group LLC now owns 12,000 shares of the company’s stock worth $42,000 after purchasing an additional 7,000 shares in the last quarter. Institutional investors own 1.90% of the company’s stock.
Longeveron Inc, a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors.
Featured Article: How does inflation affect different investments?
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.